MGP Database

New search | Record Overview | Ontology/Pathway Information | Domain Information | UniProt Annotations | Related Proteins
MGP001856

UniProt Annotations

Entry Information
Gene NameSMAD family member 3
Protein EntrySMAD3_HUMAN
UniProt IDP84022
SpeciesHuman
Comments
Comment typeDescription
Alternative ProductsEvent=Alternative splicing; Named isoforms=4; Name=1; IsoId=P84022-1; Sequence=Displayed; Name=2; IsoId=P84022-2; Sequence=VSP_042900; Note=No experimental confirmation available.; Name=3; IsoId=P84022-3; Sequence=VSP_043793; Name=4; IsoId=P84022-4; Sequence=VSP_045348; Note=No experimental confirmation available.;
DiseaseColorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. Note=The disease may be caused by mutations affecting the gene represented in this entry.
DiseaseLoeys-Dietz syndrome 3 (LDS3) [MIM:613795]: An aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Patients with LDS3 also manifest early-onset osteoarthritis. They lack craniosynostosis and mental retardation. {ECO:0000269|PubMed:21217753, ECO:0000269|PubMed:21778426}. Note=The disease is caused by mutations affecting the gene represented in this entry. SMAD3 mutations have been reported to be also associated with thoracic aortic aneurysms and dissection (TAAD) (PubMed:21778426). This phenotype is distinguised from LDS3 by having aneurysms restricted to thoracic aorta. As individuals carrying these mutations also exhibit aneurysms of other arteries, including abdominal aorta, iliac, and/or intracranial arteries (PubMed:21778426), they have been classified as LDS3 by the OMIM resource. {ECO:0000269|PubMed:21778426}.
DomainThe linker region is required for the TGFbeta-mediated transcriptional activity and acts synergistically with the MH2 domain.
DomainThe MH1 domain is required for DNA binding. Also binds zinc ions which are necessary for the DNA binding.
DomainThe MH2 domain is required for both homomeric and heteromeric interactions and for transcriptional regulation. Sufficient for nuclear import.
FunctionReceptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF- mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. {ECO:0000269|PubMed:10995748, ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252, ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:9732876, ECO:0000269|PubMed:9892009}.
InteractionSelf; NbExp=3; IntAct=EBI-347161, EBI-347161; Q9H2X0:CHRD; NbExp=2; IntAct=EBI-347161, EBI-947551; P98082:DAB2; NbExp=3; IntAct=EBI-347161, EBI-1171238; Q9BZ29:DOCK9; NbExp=3; IntAct=EBI-347161, EBI-2695893; Q99814:EPAS1; NbExp=2; IntAct=EBI-347161, EBI-447470; Q9NYA4:MTMR4; NbExp=4; IntAct=EBI-347161, EBI-1052346; Q99836:MYD88; NbExp=3; IntAct=EBI-347161, EBI-447677; Q16822:PCK2; NbExp=2; IntAct=EBI-347161, EBI-2825219; Q9BZL4:PPP1R12C; NbExp=2; IntAct=EBI-347161, EBI-721802; Q96EP0:RNF31; NbExp=2; IntAct=EBI-347161, EBI-948111; Q9BYW2:SETD2; NbExp=2; IntAct=EBI-347161, EBI-945869; P12755:SKI; NbExp=2; IntAct=EBI-347161, EBI-347281; Q15796:SMAD2; NbExp=2; IntAct=EBI-347161, EBI-1040141; Q13485:SMAD4; NbExp=17; IntAct=EBI-347161, EBI-347263; Q9HAU4:SMURF2; NbExp=5; IntAct=EBI-347161, EBI-396727; Q13573:SNW1; NbExp=5; IntAct=EBI-347161, EBI-632715; Q13501:SQSTM1; NbExp=3; IntAct=EBI-347161, EBI-307104; Q9Y3Q8:TSC22D4; NbExp=2; IntAct=EBI-347161, EBI-739485; Q93009:USP7; NbExp=2; IntAct=EBI-347161, EBI-302474; O00308:WWP2; NbExp=4; IntAct=EBI-347161, EBI-743923; Q5D1E8:ZC3H12A; NbExp=2; IntAct=EBI-347161, EBI-747793; O95405:ZFYVE9; NbExp=2; IntAct=EBI-347161, EBI-296817;
PtmAcetylation in the nucleus by EP300 in the MH2 domain regulates positively its transcriptional activity and is enhanced by TGF-beta. {ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:19413330, ECO:0000269|PubMed:22814378}.
PtmPhosphorylated on serine and threonine residues. Enhanced phosphorylation in the linker region on Thr-179, Ser-204 and Ser- 208 on EGF and TGF-beta treatment. Ser-208 is the main site of MAPK-mediated phosphorylation. CDK-mediated phosphorylation occurs in a cell-cycle dependent manner and inhibits both the transcriptional activity and antiproliferative functions of SMAD3. This phosphorylation is inhibited by flavopiridol. Maximum phosphorylation at the G(1)/S junction. Also phosphorylated on serine residues in the C-terminal SXS motif by TGFBR1 and ACVR1. TGFBR1-mediated phosphorylation at these C-terminal sites is required for interaction with SMAD4, nuclear location and transactivational activity, and appears to be a prerequisite for the TGF-beta mediated phosphorylation in the linker region. Dephosphorylated in the C-terminal SXS motif by PPM1A. This dephosphorylation disrupts the interaction with SMAD4, promotes nuclear export and terminates TGF-beta-mediated signaling. Phosphorylation at Ser-418 by CSNK1G2/CK1 promotes ligand- dependent ubiquitination and subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-beta responses. Phosphorylated by PDPK1. {ECO:0000269|PubMed:11224571, ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252, ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:18669648, ECO:0000269|PubMed:18794808, ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:21947082, ECO:0000269|PubMed:8774881, ECO:0000269|PubMed:9843571}.
PtmPoly-ADP-ribosylated by PARP1 and PARP2. ADP-ribosylation negatively regulates SMAD3 transcriptional responses during the course of TGF-beta signaling. {ECO:0000269|PubMed:25133494}.
PtmUbiquitinated. Monoubiquitinated, leading to prevent DNA- binding. Deubiquitination by USP15 alleviates inhibition and promotes activation of TGF-beta target genes. {ECO:0000269|PubMed:21947082}.
SimilarityBelongs to the dwarfin/SMAD family. {ECO:0000305}.
SimilarityContains 1 MH1 (MAD homology 1) domain. {ECO:0000255|PROSITE-ProRule:PRU00438}.
SimilarityContains 1 MH2 (MAD homology 2) domain. {ECO:0000255|PROSITE-ProRule:PRU00439}.
Subcellular LocationCytoplasm. Nucleus. Note=Cytoplasmic and nuclear in the absence of TGF-beta. On TGF-beta stimulation, migrates to the nucleus when complexed with SMAD4. Through the action of the phosphatase PPM1A, released from the SMAD2/SMAD4 complex, and exported out of the nucleus by interaction with RANBP1. Co-localizes with LEMD3 at the nucleus inner membrane. MAPK-mediated phosphorylation appears to have no effect on nuclear import. PDPK1 prevents its nuclear translocation in response to TGF-beta.
SubunitMonomer; in the absence of TGF-beta. Homooligomer; in the presence of TGF-beta. Heterotrimer; forms a heterotrimer in the presence of TGF-beta consisting of two molecules of C-terminally phosphorylated SMAD2 or SMAD3 and one of SMAD4 to form the transcriptionally active SMAD2/SMAD3-SMAD4 complex. Interacts with TGFBR1. Part of a complex consisting of AIP1, ACVR2A, ACVR1B and SMAD3. Interacts with AIP1, TGFB1I1, TTRAP, FOXL2, PML, PRDM16, HGS, WWP1 and SNW1. Interacts (via MH2 domain) with CITED2 (via C- terminus). Interacts with NEDD4L; the interaction requires TGF- beta stimulation. Interacts (via the MH2 domain) with ZFYVE9. Interacts with HDAC1, VDR, TGIF and TGIF2, RUNX3, CREBBP, SKOR1, SKOR2, SNON, ATF2, SMURF2 and TGFB1I1. Interacts with DACH1; the interaction inhibits the TGF-beta signaling. Forms a complex with SMAD2 and TRIM33 upon addition of TGF-beta. Found in a complex with SMAD3, RAN and XPO4. Interacts in the complex directly with XPO4. Interacts (via the MH2 domain) with LEMD3; the interaction represses SMAD3 transcriptional activity through preventing the formation of the heteromeric complex with SMAD4 and translocation to the nucleus. Interacts with RBPMS. Interacts (via MH2 domain) with MECOM. Interacts with WWTR1 (via its coiled-coil domain). Interacts (via the linker region) with EP300 (C-terminal); the interaction promotes SMAD3 acetylation and is enhanced by TGF-beta phosphorylation in the C-terminal of SMAD3. This interaction can be blocked by competitive binding of adenovirus oncoprotein E1A to the same C-terminal site on EP300, which then results in partially inhibited SMAD3/SMAD4 transcriptional activity. Interacts with SKI; the interaction represses SMAD3 transcriptional activity. Component of the multimeric complex SMAD3/SMAD4/JUN/FOS which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF-beta. Interacts (via an N-terminal domain) with JUN (via its basic DNA binding and leucine zipper domains); this interaction is essential for DNA binding and cooperative transcriptional activity in response to TGF-beta. Interacts with PPM1A; the interaction dephosphorylates SMAD3 in the C-terminal SXS motif leading to disruption of the SMAD2/3-SMAD4 complex, nuclear export and termination of TGF-beta signaling. Interacts (dephosphorylated form via the MH1 and MH2 domains) with RANBP3 (via its C-terminal R domain); the interaction results in the export of dephosphorylated SMAD3 out of the nucleus and termination of the TGF-beta signaling. Interacts with MEN1. Interacts with IL1F7. Interaction with CSNK1G2. Interacts with PDPK1 (via PH domain). Interacts with DAB2; the interactions are enhanced upon TGF-beta stimulation. Interacts with USP15. Interacts with PPP5C; the interaction decreases SMAD3 phosphorylation and protein levels. Interacts with LDLRAD4 (via the SMAD interaction motif). Interacts with PMEPA1. {ECO:0000269|PubMed:10995748, ECO:0000269|PubMed:11224571, ECO:0000269|PubMed:11274402, ECO:0000269|PubMed:11278756, ECO:0000269|PubMed:11387212, ECO:0000269|PubMed:11427533, ECO:0000269|PubMed:12154125, ECO:0000269|PubMed:12686552, ECO:0000269|PubMed:14525983, ECO:0000269|PubMed:15350224, ECO:0000269|PubMed:15561701, ECO:0000269|PubMed:15588252, ECO:0000269|PubMed:15601644, ECO:0000269|PubMed:15647271, ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:15897867, ECO:0000269|PubMed:16200078, ECO:0000269|PubMed:16449645, ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:17099224, ECO:0000269|PubMed:17292623, ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:18568018, ECO:0000269|PubMed:18794808, ECO:0000269|PubMed:19049980, ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:20129061, ECO:0000269|PubMed:20935647, ECO:0000269|PubMed:21947082, ECO:0000269|PubMed:22781750, ECO:0000269|PubMed:24627487, ECO:0000269|PubMed:9311995, ECO:0000269|PubMed:9665135, ECO:0000269|PubMed:9670020, ECO:0000269|PubMed:9732876, ECO:0000269|PubMed:9843571, ECO:0000269|PubMed:9865696, ECO:0000269|PubMed:9892009}.
  logo